For how we live.
6 articles published between February 24, 2026 and October 18, 2026.
A 60-woman phase 2A trial found the dual PPAR agonist reduced liver fat by nearly 15 percentage points more than placebo over 24 weeks — an early, small signal in a group usually left out of fatty-liver drug trials.
In a 76-woman randomised trial, a six-hour daily eating window and standard calorie restriction each produced about a 4% weight loss over six months, with no advantage for either approach.
Using genetic variants as instruments, researchers found exercise and wellbeing lowered risk of PCOS, endometriosis and menstrual disorders, while screen time and mood swings raised it.
Semaglutide showed a sixfold reporting signal for polycystic ovary syndrome and a smaller but real alopecia signal. Dulaglutide and tirzepatide showed lower or no signal for the same reproductive events.
An 876-participant double-blind trial across 24 Chinese fertility centres nearly doubled serum 25-OHD in women with PCOS. Live births were 52.0% against 50.2% on placebo.
A double-blind trial randomised 750 women with polycystic ovary syndrome to one drug or the other. Letrozole produced more live births and more ovulation — and is now the guideline's first choice for fertility.